10-Q: CDT Equity Reports Wider Loss Amid Strategic AI Pivot

CDT Equity Inc. reported a wider net loss for the first half of 2025 despite significant capital raises, as it pivots to an AI-driven biotech development strategy and expands its asset portfolio.

Summary

• Net loss for the six months ended June 30, 2025, widened to $10.8 million, compared to $8.9 million for the same period in 2024.
• Research and development expenses surged by 1,714% to $2.8 million for the six months ended June 30, 2025, primarily due to new agreements with Sarborg and Thesprogen.
• Cash and cash equivalents increased significantly to $3.3 million as of June 30, 2025, from $0.6 million at December 31, 2024, driven by financing activities.
• Total liabilities decreased substantially to $4.5 million as of June 30, 2025, from $11.0 million at December 31, 2024, largely due to repayment and conversion of convertible notes.
• Stockholders' equity shifted from a deficit of $(6.8) million at December 31, 2024, to a positive $3.5 million at June 30, 2025.
• The company changed its name to CDT Equity Inc. on August 5, 2025, reflecting a strategic evolution towards a data-driven biotech development platform leveraging AI and solid-form chemistry.
• An At-the-Market (ATM) offering raised $11.9 million net proceeds during the six months ended June 30, 2025, with $8.0 million remaining available.
• A share repurchase program of up to $1.0 million was authorized on April 10, 2025, with 11,713 shares repurchased as of June 30, 2025.

Sentiment

Score: 3

Explanation: While the company has successfully raised capital and is pursuing an innovative AI-driven strategy, the significant increase in net loss, higher cash burn, and explicit 'going concern' warning indicate severe financial distress and high operational risk. The strategic pivot is promising but unproven, and the company's ability to secure future funding remains uncertain.

Positives

• Cash and cash equivalents increased significantly to $3.3 million as of June 30, 2025, from $0.6 million at December 31, 2024.
• Total liabilities decreased substantially to $4.5 million as of June 30, 2025, from $11.0 million at December 31, 2024.
• Stockholders' equity shifted from a deficit of $(6.8) million to a positive $3.5 million, indicating an improved financial structure.
• Successfully raised $11.9 million net through the At-the-Market (ATM) program, with $8.0 million still available for future funding.
• Strategic pivot to a data-driven biotech development model leveraging AI and solid-form chemistry aims for accelerated development and extended patent life.
• Established new partnerships with Sarborg for AI-powered disease mapping and Charles River Laboratories for preclinical testing.
• Entered a joint development agreement with Manoira Corporation to explore animal health applications for existing assets, potentially informing human clinical programs and opening new revenue streams.
• Regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements, and successfully transferred to The Nasdaq Capital Market.

Negatives

• Net loss widened to $10.8 million for the six months ended June 30, 2025, compared to $8.9 million for the same period in 2024.
• Cash used in operating activities increased to $6.5 million for the six months ended June 30, 2025, from $3.9 million in the prior year, indicating a higher cash burn rate.
• Accumulated deficit increased to $39.9 million as of June 30, 2025, from $29.1 million at December 31, 2024.
• Management has determined that it does not have sufficient cash and other sources of liquidity to fund its current business plan, raising substantial doubt about its ability to continue as a going concern.
• Ongoing legal proceedings, including a claim for $2.0 million in advisory fees and 4,333 shares, and a dispute over the sole ownership of the AZD 1656 co-crystal patent, pose financial and operational risks.
• Increased research and development expenses, while strategic, contribute to the higher net loss and cash burn.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for at least the next 12 months due to significant losses and negative operating cash flows.
• There is no assurance that additional funding will be available when needed or on acceptable terms, which could lead to delays or curtailment of operations and R&D activities.
• While compliance with certain Nasdaq rules has been regained, there is no guarantee of maintaining ongoing compliance with listing rules.
• Ongoing legal proceedings, including a $2.0 million claim from Strand Hanson Limited and a dispute over the AZD 1656 co-crystal patent, could result in significant legal costs and diversion of management attention, potentially impacting business, financial condition, and operating results.
• The company is subject to uncertainties related to pre-clinical and clinical outcomes, competitor products, regulatory approvals, dependence on key products, dependence on key suppliers, and protection of intellectual property rights.
• Breach or termination of the license agreement with AstraZeneca could have a material adverse effect on the company's business.
• Transactions with related parties (e.g., Sarborg, Manoira, Nirland) increase the risk of omissions or misstatements, non-arms length terms, and potential conflicts of interest.
• Future equity or convertible debt financings could dilute existing stockholders' ownership interests.
• Market data projections based on assumptions may be incorrect, leading to actual results differing from projections and potentially harming the business.

Future Outlook

The company expects to generate operating losses and negative operating cash flows in the future and will need additional funding beyond its current At-the-Market (ATM) program to support its business plan. It plans to pursue additional cash resources through public or private equity or debt financings. The strategic focus remains on accelerating the development of novel treatments by leveraging AI, solid-form chemistry, and efficient asset repositioning, with an aim to exit through third-party license deals following successful pre-clinical trials. The Board is also evaluating a cryptocurrency treasury reserve strategy for potential strategic and financial benefits.

Management Comments

• "Our change to CDT Equity Inc. reflects the evolution of our strategy as a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships."
• "Our strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies with strong, supporting Phase I safety data."
• "Operating with a lean, asset-agnostic model, CDT Equity prioritizes speed, adaptability, and capital efficiency. We avoid the cost burden of late-stage clinical trials, focusing instead on high-leverage development strategies."
• "The Sarborg Agreement... is designed to address longstanding challenges in the pharmaceutical sector, in particular by reducing human error in critical decision-making processes in both clinical development and asset identification."
• "By integrating Sarborgs algorithmic AI/cybernetics technology, CDT aims to enhance efficiency, lower costs, and accelerate timelines by minimizing human intervention, ultimately optimizing the drug development cycle and giving CDT a competitive advantage in the sector."
• "A further partnership with Manoira enables CDT Equity to expand the scope of its drug portfolio into the animal health market in a cost-efficient manner."
• "The Board continue to evaluate a cryptocurrency treasury reserve strategy, working with consultants to best advise a novel market which has seen significant recent activity and success for respective stakeholders. Long-term exposure to digital assets can present both strategic and financial benefits as part of a diversified capital management approach."
• "We plan to focus our efforts on developing clinical assets to address disorders that impact a large population where there is no present treatment or the present treatment, carries significant unwanted side effects."

Industry Context

The company operates in the pharmaceutical development industry, with a distinct focus on repositioning clinical-stage compounds. Its strategy of leveraging AI and solid-form chemistry for drug development and patent extension aligns with broader industry trends towards enhancing efficiency, fostering innovation, and maximizing intellectual property in drug discovery. The emphasis on 'deprioritized' assets from larger pharmaceutical companies represents a niche strategy to find value in compounds that have already undergone initial safety testing. The exploration of animal health markets and a cryptocurrency treasury reserve strategy indicates a diversification beyond traditional pharmaceutical development, potentially reflecting a broader 'equity' investment approach.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against.
• The company's strategy of avoiding late-stage clinical trials and focusing on licensing after pre-clinical/early clinical data is a departure from the traditional biotech model, which typically involves significant capital expenditure on Phase II/III trials. This makes direct financial comparisons difficult without more context on similar 'asset repositioning' firms.
• The high R&D expense increase (1,714%) is significant but needs to be viewed in the context of a small base and new strategic partnerships (Sarborg, Charles River).
• The explicit 'going concern' warning is a critical indicator that the company's financial health is below industry standards for stable, revenue-generating biotech firms.

Management Changes

Corporate Governance

Legal Proceedings

• Strand Hanson Limited filed a claim in the Business and Property Courts of England and Wales for $2.0 million in advisory fees and 4,333 shares of Common Stock; trial scheduled for October 20, 2025. The company has accrued an estimated liability of $0.4 million.
• St George Street Capital filed formal complaints with the Intellectual Property Office claiming the company was not the sole owner of the AZD 1656 co-crystal patent; the company disputes this claim, and the range of possible loss cannot be estimated and is not considered probable.

Related Party Transactions

• Prepaid R&D services-related party balance of $1,626,000 as of June 30, 2025.
• August 2024 Nirland Note: Entered into with Nirland Limited (related party), which was repaid in full by February 12, 2025.
• October 2024 Nirland Note: Issued to Nirland Limited (related party), with no obligations remaining as of June 30, 2025.
• SARBORG Service Agreement: Entered into with SARBORG Limited (related party, Dr. Andrew Regan on board), for algorithmic and cybernetic technology services, involving an initial payment of $0.2 million cash and 1,515 shares, with milestone payments up to $1.8 million.
• SARBORG Additional Agreement: Entered into with SARBORG Limited (related party), for additional deliverables and analysis of AstraZeneca assets, involving a payment of $2.0 million, prepaid $1.65 million via 123,595 shares.
• Manoira Joint Development Agreement: Entered into with Manoira Corporation (related party, controlled by Dr. Andrew Regan, Chele Farley is sole director), for evaluation of AZD1656 and AZD5658 in animal health, involving the issuance of 154,799 shares ($0.4 million fair value).
• Director travel expenses payable to Dr. Andrew Regan of approximately $0.3 million for both the three and six months ended June 30, 2025.
• Officers and Directors received 605 April 2024 Warrants in exchange for lock-up agreements and $187.50 per warrant.

Stakeholder Impact

• Shareholders: Experienced significant dilution from the ATM program and convertible note conversions, though a share repurchase program aims to mitigate this. The Nasdaq listing transfer provides continued market access. Potential for future dilution from additional capital raises.
• Employees: Stock-based compensation is a component of their remuneration. Management changes (new CEO, permanent CFO) could impact organizational structure and culture.
• Customers/Partners: New agreements with Sarborg, Charles River, and Manoira indicate active development and collaboration, potentially leading to new products or services.
• Creditors: Convertible notes and other loans have been repaid or converted, reducing immediate debt obligations, but new debt or equity raises are anticipated.
• Regulatory Authorities: Ongoing compliance with Nasdaq listing rules and SEC reporting requirements is critical.

Next Steps

• Generate operating losses and negative operating cash flows in the future.
• Need additional funding to support the current business plan.
• Pursue additional cash resources through public or private equity or debt financings.
• Delay or curtail operations and R&D activities if additional funding is not available.
• Seek an exit through third-party license deals following successful in vitro and in vivo pre-clinical trials.
• Continue to evaluate novel artificial intelligence and cybernetics approaches to drug re-purposing, intellectual property, and asset selection.
• Continue to evaluate a cryptocurrency treasury reserve strategy.
• Trial for Strand Hanson Limited claim scheduled for October 20, 2025.
• Sarborg to expand scope of Additional Agreement to provide external analysis of third-party pharma companies' assets suitable for drug re-purposing (effective July 1, 2025).
• Sarborg to integrate a Cryptocurrency AI Agent into CDT Equity's Operations as part of its Treasury Strategy (effective August 11, 2025).

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern, evidenced by widening net losses and increased cash burn. While recent capital raises have temporarily improved the balance sheet, the underlying operational losses are significant, and future funding is uncertain. Ongoing legal disputes add further risk and potential financial strain. The strategic pivot to AI-driven drug development is innovative but highly speculative and long-term, offering no immediate path to profitability. Given the severe liquidity concerns and high operational risk, a seasoned investor would likely recommend selling to avoid potential further capital erosion.

Keywords

Biotech, Pharmaceuticals, Drug Development, Artificial Intelligence, AI, Clinical Assets, SEC Filing, 10-Q, Nasdaq, AZD1656, AZD5658, AZD5904, Autoimmune Disorders, Male Infertility, Oncology, Dermatology, Animal Health, Co-crystallization, Patent Life Extension, Sarborg, AstraZeneca, Going Concern, Capital Raise